Targeted Prodrug Therapy of Liver Cancers
Award last edited on: 8/3/04

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
John Y Chan

Company Information

Acclaim Biotechnology Inc

3520 Plumb Street
Houston, TX 77005
   (713) 669-1898
Location: Single
Congr. District: 07
County: Harris

Phase I

Contract Number: 1R43CA105617-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
Phase I Amount
Hepatocellular carcinoma (HCC) and colorectal cancer (CRC) are among the most common and deadly malignancy worldwide. CRC is the second leading cause of cancer-related death in the USA, mostly due to metastases to the liver. 5-fluorouracil (5-FU) remains the mainstay of combination chemotherapy for liver cancers including non-resectable liver metastases. Recent studies demonstrated that regional 5-FU-based chemotherapy by directly hepatic infusion showed improved response rates and survival for CRC patients as compared with those with systemic treatment. However, this delivery system is technically complicated, highly invasive, risky and costly. The present application is a patented delivery system for improved chemotherapy of liver cancer and metastasis. It utilizes a recombinant fusion protein consisted of the malarial circumsporozoite (CS) protein, a hepatocyte-specific targeting ligand, linked to the bacterial cytosine deaminase (CD), a suicidal gene product which catalyzes the production of 5-FU from its prodrug 5- fluorocytosine (5-FC). We have demonstrated that the CD-CS fusion protein can be internalized in a cell type-specific manner. More importantly, the internalized protein is stable for at least four weeks and exerts bystander cell-killing effects upon the administration of the prodrug 5-FC. The prolonged stability can be attributed to the fact that the internalized fusion protein is entrapped in the particular compartment(s) that are free from the cytoplasmic degradation machinery. To further develop and commercialize this system, we propose the following 2 specific aims: (1) to construct deletion mutants and modified versions of CD-CS for increasing yield, stability and activity of the fusion protein; and (2) to optimize the production of the modified CD-CS protein and to determine their effectiveness in scale-up preparations for product manufacturing and future clinical trials. This novel prodrug targeting therapy is effective, technically simple, non-invasive and cost effective, which should have enormous commercial potential.

Thesaurus Terms:
chimeric protein, liver neoplasm, neoplasm /cancer chemotherapy, prodrug, protein engineering, recombinant protein aminohydrolase, bacterial protein, circumsporozoite protein, colorectal neoplasm, flucytosine, fluorouracil, gene deletion mutation, hepatocellular carcinoma, metastasis, mutant biotechnology, cell line

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount